1 not yet recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Cemiplimab+Fianlimab Fixed Dose Combination (FDC): new trials by email Literature Review of Cemiplimab+Fianlimab Fixed Dose Combination (FDC) trials Research Report on Cemiplimab+Fianlimab Fixed Dose Combination (FDC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC) - High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 120 | 2026-08-31 | 2026-05-05 |
Ependymoma (1) · Glioma (1) · Neoplasms (1) · Recurrence (1)
2025 (1)